Maintenance treatment in bipolar disorder: A focus on aripiprazole

Expert Review of Neurotherapeutics

Volumn 7, Issue 8, 2007, Pages 919-925

  McIntyre, Roger S ^a,b   Woldeyohannes, Hanna O ^b   Yasgur, Batya S ^c   Soczynska, Joanna K ^a,b   Miranda, Andrew ^b   Konarski, Jakub Z ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Mood Disorders Psychopharmacology Unit ^*

Author keywords

Antipsychotic; Aripiprazole; Bipolar disorder; Maintenance; Pharmacology

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; CLOZAPINE; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LITHIUM; OLANZAPINE; OXCARBAZEPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

AKATHISIA; ANXIETY; BIPOLAR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DEPRESSION; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPERANDROGENISM; INSOMNIA; LIVER TOXICITY; METABOLIC DISORDER; MONOTHERAPY; MORTALITY; MUSCLE HYPERTONIA; NERVOUSNESS; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PANCREATITIS; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TERATOGENICITY; TREMOR; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; HUMANS; PIPERAZINES; QUINOLONES; TIME;

EID: 34548057222     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.8.919     Document Type: Review

References (60)

1. McIntyre RS, Konarski JZ. Bipolar disorder: a national health concern. CNS Spectr. 9(11 Suppl. 12), 6-15 (2004).
2. Hirschfeld RM, Vornik LA. Bipolar disorder - costs and comorbidity. Am. J. Manag. Care 11(Suppl. 3), S85-S90 (2005).
3. Kessler RC, Akiskal HS, Ames M et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry 163(9), 1561-1568 (2006).
4. Begley CE, Annegers JF, Swann AC et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 19(5 Pt 1), 483-495 (2001).
5. Greenberg PE, Kessler RC, Birnbaum HG et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J. Clin. Psychiatry 64(12), 1465-1475 (2003).
6. Osby U, Brandt L, Correia N et al. Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 58(9), 844-850 (2001).
7. Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord. 7(Suppl. 3), 5-69 (2005). • Recommended guidelines for treatment of bipolar disorder.
8. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J. Clin. Psychiatry 2, 161-174 (2003).
9. Smith DJ, Harrison N, Muir W et al. The high prevalence of bipolar spectrum disorders in young adults with recurrent depression: toward an innovative diagnostic framework. J. Affect. Disord. 84(2-3), 167-178 (2005).
10. Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol. Psychiatry 6, 558-572 (2000).
11. Suppes T, Dennehy EB, Hirschfeld RM et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J. Clin. Psychiatry 66(7), 870-886 (2005).
12. Miklowitz DJ, Otto MW, Frank E et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the systematic treatment enhancement program. Arch. Gen. Psychiatry 64(4), 419-426 (2007).
13. McIntyre RS, Mancini DA, Parikh S et al. Lithium revisited. Can. J. Psychiatry 46(4), 322-327 (2001).
14. Grof P. Has the effectiveness of lithium changed? Impact of the variety of lithium's effects. Neuropsychopharmacology 19(3), 183-188 (1998).
15. Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am. J. Psychiatry 161(1), 3-18 (2004).
16. Maj M, Pirozzi R, Magliano L et al. Agitated depression in bipolar I disorder: prevalence, phenomenology, and outcome. Am. J. Psychiatry 160(12), 2134-2140 (2003).
17. Chou JC, Fazzio L. Maintenance treatment of bipolar disorder: applying research to clinical practice. J. Psychiatr. Pract. 12(5), 283-299 (2006).
18. Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr. 11(6), 465-471 (2006).
19. Swann AC, Bowden CL, Morris D et al. Depression during mania. Treatment response to lithium or divalproex. Arch. Gen. Psychiatry 54(1), 37-42 (1997).
20. Geddes JR, Burgess S, Hawton K et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am. J. Psychiatry 161(2), 217-222 (2004).
21. Zarate CA Jr, Tohen M, Narendran R et al. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J. Clin. Psychiatry 60(4), 232-236 (1999).
22. McElroy SL, Keck PE Jr, Pope HG Jr et al. Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. J. Clin. Psychopharmacol. 12(Suppl. 1), S42-S52 (1992).
23. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am. J. Psychiatry 159(Suppl. 4), 1-50 (2002).
24. Gyulai L, Bowden CL, McElroy SL et al. Maintenance efficacy of divalproex in the prevention of bipolar depression. Neuropsychopharmacology 28(7), 1374-1382 (2003).
25. Bowden CL, Calabrese JR, McElroy SL et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen. Psychiatry 57(5), 481-489 (2000).
26. McIntyre RS, Mancini DA, McCann S et al. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord. 5(1), 28-35 (2003).
27. Joffe H, Cohen LS, Stuppes T et al. Polycystic ovarian syndrome is associated with valproate use in bipolar women. Presented at: American Psychiatric Association 154th Annual Conference. New York, NY, USA, 1-6 May 2004.
28. Joffe H, Cohen LS, Suppes T et al. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol. Psychiatry 60(12), 1378-1381 (2006).
29. O'Donovan C, Kusumakar V, Graves GR et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J. Clin. Psychiatry 63(4), 322-330 (2002).
30. Joffe H, Cohen LS, Suppes T et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol. Psychiatry 59(11), 1078-1086 (2006).
31. Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J. Clin. Psychiatry 65(3), 432-441 (2004).
32. Calabrese JR, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J. Clin. Psychiatry 64(9), 1013-1024 (2003).
33. Calabrese JR, Bowden CL, Sachs GS et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J. Clin. Psychiatry 60(2), 79-88 (1999).
34. Lieberman JA. Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch. Gen. Psychiatry 63(10), 1069-1072 (2006).
35. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry 66(3), 28-36 (2005).
36. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353(12), 1209-1223 (2005).
37. Goldberg JF, Citrome L. Latest therapies for bipolar disorder. Looking beyond lithium. Postgrad. Med. 117(2), 25-32, 35 (2005).
38. Dando S, Tohen M. Olanzapine - relapse prevention following mania. J. Psychopharmacol. 20(Suppl. 2), 31-38 (2006).
39. Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am. J. Psychiatry 161(1), 169-171 (2004).
40. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry 66(Suppl. 3), 28-36 (2005). •• Pharmacodynamic profile of aripiprazole.
41. Stahl SM. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J. Clin. Psychiatry 62(12), 923-924 (2001).
42. Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann. Pharmacother. 37(5), 687-694 (2003).
43. McIntyre RS, Soczynska JK, Woldeyohannes HO et al. Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin. Pharmacother. 8(7), 1001-1009 (2007).
44. Aihara K, Shimada J, Miwa T et al. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release. Brain Res. 1003(1-2), 9-17 (2004). •• Aripiprazole's unique pharmacodynamic profile.
45. Tadori Y, Miwa T, Tottori K et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur. J. Pharmacol. 515(1-3), 10-19 (2005). •• Aripiprazole's unique pharmacodynamic profile.
46. Keck PE Jr, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry 67(4), 626-637 (2006).
47. Wood MD, Scott C, Clarke K et al. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur. J. Pharmacol. 546(1-3), 88-94 (2006).
48. Chessick CA, Allen MH, Thase M et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst. Rev. 3, CD006115 (2006). • Aripiprazole's pharmacodynamic profile.
49. Keck PE, Calabrese JR, McQuade RD et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J. Clin. Psychiatry 67(4), 626-637 (2006). •• Randomized controlled trial with aripiprazole in the maintenance therapy of bipolar disorder.
50. Bowden CL, Calabrese JR, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch. Gen. Psychiatry 60(4), 392-400 (2003).
51. Tohen M, Calabrese JR, Sachs GS et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am. J. Psychiatry 163(2), 247-256 (2006).
52. Judd LL, Akiskal HS, Schettler PJ et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry 60(3), 261-269 (2003).
53. Judd LL, Schettler PJ, Akiskal HS et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int. J. Neuropsychopharmacol. 6(2), 127-137 (2003).
54. McIntyre RS. Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited. J. Clin. Psychiatry 63(Suppl. 3), 15-20 (2002).
55. McIntyre RS, Konarski JZ, Wilkins K et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can. J. Psychiatry 51, 274-280 (2006).
56. McIntyre RS, Konarski JZ, Misener VL et al. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann. Clin. Psychiatry 17(2), 83-93 (2005).
57. Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders. J. Clin. Psychiatry 60(Suppl. 2), 77-84 (1999).
58. Tohen M, Greil W, Calabrese JR et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial. Am. J. Psychiatry 162, 1281-1290 (2005).
59. Ketter TA, Wang PW, Chandler RA et al. Adjunctive aripiprazole in treatment-resistant bipolar depression. Ann. Clin. Psychiatry 18(3), 169-172 (2006).
60. Hirose T, Kikuchi T. Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J. Med. Invest. 52(Suppl.), 284-290 (2005).